TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced the launch of its validated 27-pathogen urinary tract infection (UTI) PCR precision medicine panel at its CLIA/CAP-certified laboratory, Provista Diagnostics. This advanced test offers greater sensitivity and faster results (24-48 hours) compared to traditional cell culture methods (3-7 days). Targeting skilled nursing facilities and women's health specialists, this testing aims to improve patient outcomes by enhancing therapy selection. The company is also expanding its focus on precision diagnostics with plans to develop additional assays for conditions like Long COVID.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a Day 45 update from a study on its 3CL protease inhibitor, Tollovid, used by a patient suffering from Long COVID. The subject reported significant improvement in symptoms after starting Tollovid, experiencing a 90-95% relief within five days. Despite previous treatments failing due to adverse effects, the subject noted a return to 85% of his pre-COVID condition after continuing with Tollovid. The study highlights Tollovid's potential efficacy in managing Long COVID symptoms.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its subsidiary 3CL Pharma, Ltd. provided a Day 28 update from a case study on Tollovid, a dietary supplement. The patient, a 36-year-old male suffering from Long COVID symptoms, reported significant improvements after taking Tollovid for 10 days. Key benefits included normalization of stool and reduced inflammation and fatigue. The study suggests Tollovid may help manage symptoms related to viral persistence in Long COVID. Further investigations into Tollovid's efficacy for erectile dysfunction are planned.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its President and CEO, Gerald Commissiong, will present at the LD Micro Conference on June 8, 2022, at 1:30 PST. The company specializes in medical diagnostics, focusing on early cancer detection using its proprietary Todos Biochemical Infrared Analyses (TBIA) technology. Todos has developed cancer-screening tests TMB-1 and TMB-2, which have received a CE mark in Europe, and has acquired Provista Diagnostics to enhance its capabilities. For more details, visit www.todosmedical.com.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced the full enrollment of the 2nd cohort in a clinical trial led by Dr. Thomas Arendt at Leipzig University, evaluating the LymPro Alzheimer’s Blood Test in relation to amyloid PET imaging scores. Data from this trial is expected in summer 2022. The LymPro Test™, a potential early diagnostic for Alzheimer's, uses lymphocytes as indicators of neuronal function. With over 5.4 million Alzheimer's patients in the U.S., the disease incurs substantial healthcare costs, emphasizing the need for effective diagnostic tools.

Todos Medical, Ltd. (OTCQB: TOMDF) reported significant findings from a 60-day case study on its protease inhibitor dietary supplement, Tollovid, administered to a patient suffering from Long COVID. The patient, originally diagnosed with COVID-19 in March 2021, experienced substantial symptom improvements after using Tollovid, including better energy levels and normalized heart rate. The study emphasizes potential therapeutic benefits of Tollovid for Long COVID symptoms, suggesting that persistent SARS-CoV-2 infection may underlie these issues.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced significant developments from its CEO Gerald Commissiong. The company is expanding its Provista Diagnostics lab services to include PCR testing for additional pathogens, enhancing turnaround times. They plan to launch the Videssa® breast cancer test in early 2023 and are preparing for a clinical trial update on their Tollovir™ treatment for COVID-19. The company is also focusing on addressing Long COVID with new diagnostic tools and has strategies for capital raising through crowdfunding.

Todos Medical (OTCQB: TOMDF) announced its subsidiary 3CL Pharma will present final data from the Phase 2 clinical trial of Tollovir™ for treating severe COVID-19 patients at the PMWC on June 30, 2022. The trial's primary endpoint showed 100% improvement in patients treated with Tollovir, compared to 66% in the placebo group, with 0% mortality versus 22% in placebo. The forthcoming biomarker data aims to elucidate Tollovir's mechanism of action, supporting its development for severe COVID-19 and Long COVID treatment.

Todos Medical (OTCQB: TOMDF) announced an update from its subsidiary 3CL Pharma regarding a case study on Tollovid, a 3CL protease inhibitor, in a patient suffering from COVID-19 Rebound post-Paxlovid treatment. This case study indicates that after a 14-day regimen of Tollovid, the patient, who had been experiencing persistent symptoms and had tested positive for COVID-19, reported significant symptom resolution and tested negative for the virus. The findings highlight Tollovid's potential as a treatment option for Long COVID and underscore its 3CL protease inhibition capabilities.